OncoMatch/Clinical Trials/NCT06544720

SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas

Is NCT06544720 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SCG142 TCR-T cells for human papillomavirus associated carcinomas.

Phase 1RecruitingThe Affiliated Hospital of Qingdao UniversityNCT06544720Data as of May 2026

Treatment: SCG142 TCR-T cells — A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Penile Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify